| 1 | clinical trial supply services | | | | | | | 3 | 0.81% |
| 2 | solid dose commercial manufacturing | | | | | | | 3 | 0.81% |
| 3 | of tedor pharma inc | | | | | | | 1 | 0.27% |
| 4 | gmp laboratories ensure we | | | | | | | 1 | 0.27% |
| 5 | controlled substances schedules ii | | | | | | | 1 | 0.27% |
| 6 | manufacture controlled substances schedules | | | | | | | 1 | 0.27% |
| 7 | development and validation services | | | | | | | 1 | 0.27% |
| 8 | to manufacture controlled substances | | | | | | | 1 | 0.27% |
| 9 | licensed to manufacture controlled | | | | | | | 1 | 0.27% |
| 10 | and inspected and dea | | | | | | | 1 | 0.27% |
| 11 | registered and inspected and | | | | | | | 1 | 0.27% |
| 12 | our multiple wellfitted gmp | | | | | | | 1 | 0.27% |
| 13 | multiple wellfitted gmp laboratories | | | | | | | 1 | 0.27% |
| 14 | wellfitted gmp laboratories ensure | | | | | | | 1 | 0.27% |
| 15 | ensure we meet fda | | | | | | | 1 | 0.27% |
| 16 | laboratories ensure we meet | | | | | | | 1 | 0.27% |
| 17 | with our highquality process | | | | | | | 1 | 0.27% |
| 18 | fda registered and inspected | | | | | | | 1 | 0.27% |
| 19 | are fda registered and | | | | | | | 1 | 0.27% |
| 20 | we are fda registered | | | | | | | 1 | 0.27% |
| 21 | compliance requirements for characterization | | | | | | | 1 | 0.27% |
| 22 | requirements for characterization testing | | | | | | | 1 | 0.27% |
| 23 | for characterization testing analytical | | | | | | | 1 | 0.27% |
| 24 | journey we are fda | | | | | | | 1 | 0.27% |
| 25 | product’s journey we are | | | | | | | 1 | 0.27% |
| 26 | development and quality assurance | | | | | | | 1 | 0.27% |
| 27 | and quality assurance from | | | | | | | 1 | 0.27% |
| 28 | substances schedules ii through | | | | | | | 1 | 0.27% |
| 29 | ingredients apis with our | | | | | | | 1 | 0.27% |
| 30 | apis with our highquality | | | | | | | 1 | 0.27% |
| 31 | largescale commercialization with our | | | | | | | 1 | 0.27% |
| 32 | gmp manufacturing of solid | | | | | | | 1 | 0.27% |
| 33 | manufacturing of solid dose | | | | | | | 1 | 0.27% |
| 34 | of solid dose pharmaceuticals | | | | | | | 1 | 0.27% |
| 35 | solid dose pharmaceuticals at | | | | | | | 1 | 0.27% |
| 36 | dose pharmaceuticals at ranging | | | | | | | 1 | 0.27% |
| 37 | for virtual pharma companies | | | | | | | 1 | 0.27% |
| 38 | scales from smallbatch to | | | | | | | 1 | 0.27% |
| 39 | from smallbatch to largescale | | | | | | | 1 | 0.27% |
| 40 | smallbatch to largescale commercialization | | | | | | | 1 | 0.27% |